Securities and Exchange Commission

Washington, DC 20549

 

SCHEDULE 13G

 

 

 

Under the Securities Exchange Act of 1934

(Amendment No. )*

 

Corvus Pharmaceuticals, Inc.

(Name of Issuer)

 

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

 

 

 

138921115

(CUSIP Number)

 

 

 

September 21, 2021

(Date of Event Which Requires Filing of This Statement)

 

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

☐

Rule 13d-1(b)

 

ý

Rule 13d-1(c)

 

☐

Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

CUSIP No. 138921115

13G

Page 2 of 8 Pages

1	NameS of Reporting Persons I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)   TANG CAPITAL PARTNERS, LP
2	Check the Appropriate Box if a Member of a Group*	(a)  ¨ (b)  ý
3	SEC Use Only
4	Citizenship or Place of Organization   DELAWARE

Number of  Shares  BENEFICIALLY Owned by  Each Reporting Person with	5	Sole Voting Power   0
	6	Shared Voting Power   3,736,184
	7	Sole Dispositive Power   0
	8	Shared Dispositive Power   3,736,184

9	Aggregate Amount Beneficially Owned by each Reporting Person   3,736,184
10	Check Box if the Aggregate Amount in Row (9) excludes certain shares   ¨
11	Percent of Class represented by amount in row 9   8.8%
12	type of reporting person   pN

 

 

CUSIP No. 138921115

13G

Page 3 of 8 Pages

1	NameS of Reporting Persons I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)   TANG CAPITAL MANAGEMENT, LLC
2	Check the Appropriate Box if a Member of a Group*	(a)  ¨ (b)  ý
3	SEC Use Only
4	Citizenship or Place of Organization   DELAWARE

Number of  Shares  BENEFICIALLY Owned by  Each Reporting Person with	5	Sole Voting Power   0
	6	Shared Voting Power   3,736,184
	7	Sole Dispositive Power   0
	8	Shared Dispositive Power   3,736,184

9	Aggregate Amount Beneficially Owned by each Reporting Person   3,736,184
10	Check Box if the Aggregate Amount in Row (9) excludes certain shares   ¨
11	Percent of Class represented by amount in row 9   8.8%
12	type of reporting person   oo

 

 

CUSIP No. 138921115

13G

Page 4 of 8 Pages

1	NameS of Reporting Persons I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)   KEVIN TANG
2	Check the Appropriate Box if a Member of a Group*	(a)  ¨ (b)  ý
3	SEC Use Only
4	Citizenship or Place of Organization   UNITED STATES

Number of  Shares  BENEFICIALLY Owned by  Each Reporting Person with	5	Sole Voting Power   0
	6	Shared Voting Power   3,736,184
	7	Sole Dispositive Power   0
	8	Shared Dispositive Power   3,736,184

9	Aggregate Amount Beneficially Owned by each Reporting Person   3,736,184
10	Check Box if the Aggregate Amount in Row (9) excludes certain shares   ¨
11	Percent of Class represented by amount in row 9   8.8%
12	type of reporting person   IN

 

 

Item 1(a).

Name of Issuer:

 

Corvus Pharmaceuticals, Inc., a Delaware corporation (the “Issuer”)

 

Item 1(b).

Address of Issuer’s Principal Executive Offices:

 

863 Mitten Road, Suite 102, Burlingame, CA 94010

 

Item 2(a).

Name of Person Filing:

 

This Statement on Schedule 13G (this “Statement”) is filed by Tang Capital Partners, LP (“Tang Capital Partners”); Tang Capital Management, LLC, the general partner of Tang Capital Partners (“Tang Capital Management”); and Kevin Tang, the manager of Tang Capital Management.

 

Item 2(b).

Address of Principal Business Office or, if none, Residence:

 

4747 Executive Drive, Suite 210, San Diego, CA 92121

 

Item 2(c).

Citizenship:

 

Tang Capital Partners is a Delaware limited partnership. Tang Capital Management is a Delaware limited liability company. Mr. Tang is a United States citizen.

 

Item 2(d).

Title of Class of Securities:

 

Common Stock, par value $0.0001 per share (the “Common Stock”)

 

Item 2(e).

CUSIP Number: 138921115

 

Item 3.

Not applicable.

 

Item 4.

Ownership.

 

(a)

Amount Beneficially Owned:

 

Tang Capital Partners. Tang Capital Partners beneficially owns 3,736,184 shares of the Issuer’s Common Stock.

 

Tang Capital Partners shares voting and dispositive power over such shares with Tang Capital Management and Kevin Tang.

 

Tang Capital Management. Tang Capital Management beneficially owns 3,736,184 shares of the Issuer’s Common Stock.

 

Tang Capital Management shares voting and dispositive power over such shares with Tang Capital Partners and Kevin Tang.

 

Kevin Tang. Kevin Tang beneficially owns 3,736,184 shares of the Issuer’s Common Stock.

 

Kevin Tang shares voting and dispositive power over such shares with Tang Capital Partners and Tang Capital Management. 

 

 

The percentages used herein are based on 42,421,159 shares of Common Stock outstanding as of August 2, 2021, as set forth in the Issuer’s Quarterly Report on Form 10-Q that was filed with the Securities and Exchange Commission on August 2, 2021.

 

(b)

Percent of Class:

 

Tang Capital Partners	8.8%
Tang Capital Management	8.8%
Kevin Tang	8.8%

 

(c)

Number of shares as to which such person has:

 

(i)

sole power to vote or to direct the vote:

 

Tang Capital Partners	0 shares
Tang Capital Management	0 shares
Kevin Tang	0 shares

 

(ii)

shared power to vote or to direct the vote:

 

Tang Capital Partners	3,736,184 shares
Tang Capital Management	3,736,184 shares
Kevin Tang	3,736,184 shares

 

(iii)

sole power to dispose or to direct the disposition of:

 

Tang Capital Partners	0 shares
Tang Capital Management	0 shares
Kevin Tang	0 shares

 

(iv)

shared power to dispose or to direct the disposition of:

 

Tang Capital Partners	3,736,184 shares
Tang Capital Management	3,736,184 shares
Kevin Tang	3,736,184 shares

 

Item 5.

Ownership of Five Percent or Less of a Class.

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ¨

 

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

 

Not applicable

 

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

 

Not applicable.

 

Item 8.

Identification and Classification of Members of the Group.

 

Not applicable.

 

Item 9.

Notice of Dissolution of Group.

 

Not applicable.

 

 

Item 10.

Certification.

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 

Signature

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

 

Date:	September 22, 2021
TANG CAPITAL PARTNERS, LP
By:	Tang Capital Management, LLC, its General Partner
By:	/s/ Kevin Tang
	Kevin Tang, Manager
TANG CAPITAL MANAGEMENT, LLC
By:	/s/ Kevin Tang
	Kevin Tang, Manager
/s/ Kevin Tang
Kevin Tang

 

 

Page 8 of 8

 

 

Exhibit 99.1

 

JOINT FILING AGREEMENT

 

In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.0001 par value per share, of Corvus Pharmaceuticals, Inc. and further agree to the filing of this Joint Filing Agreement as an exhibit thereto. In addition, each party to this Joint Filing Agreement expressly authorizes each other party to this Joint Filing Agreement to file on its behalf any and all amendments to such Statement on Schedule 13G.

 

 

Date: September 22, 2021	TANG CAPITAL PARTNERS, LP
	By:	Tang Capital Management, LLC
	Its:	General Partner
	By:	/s/ Kevin Tang
		Name:	Kevin Tang
		Title:	Manager
	TANG CAPITAL MANAGEMENT, LLC
	By:	/s/ Kevin Tang
		Name:	Kevin Tang
		Title:	Manager
	/s/ Kevin Tang
	Name:	Kevin Tang